Halozyme Therapeutics | HALO - Cash And Equivalent


Halozyme Therapeutics reported $163.14M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
DBV Technologies USD 174.9M 54.3M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
MannKind USD 52.93M 95K Jun/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Pfizer USD 976M 727M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
United Therapeutics USD 1.8B 523.5M Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025